Technical Analysis for TYME - Tyme Technologies, Inc.

Grade Last Price % Change Price Change
grade A 3.52 -2.22% -0.08
TYME closed up 46.34 percent on Tuesday, January 15, 2019, on 4.59 times normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline.

Earnings due: Feb 6

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical TYME trend table...

Date Alert Name Type % Chg
Jan 15 Crossed Above 200 DMA Bullish -2.22%
Jan 15 Crossed Above 20 DMA Bullish -2.22%
Jan 15 Crossed Above 50 DMA Bullish -2.22%
Jan 15 Stochastic Buy Signal Bullish -2.22%
Jan 15 Expansion Pivot Buy Setup Bullish Swing Setup -2.22%
Jan 15 Pocket Pivot Bullish Swing Setup -2.22%
Jan 15 Volume Surge Other -2.22%
Jan 15 Wide Range Bar Range Expansion -2.22%
Jan 15 Wide Bands Range Expansion -2.22%
Jan 15 Gapped Up Strength -2.22%

Older signals for TYME ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Tyme Technologies, Inc., formerly Global Group Enterprises Corp., conducts majority of its research and development activities and other business operations, through its subsidiary, Tyme Inc. (Tyme). Tyme is a clinical-stage biopharmaceutical company. Tyme is focused on the development and commercialization of highly targeted cancer therapeutics with a range of oncology indications. The Company's another subsidiary, Luminant Biosciences, LLC, conducts the initial research and development of the Company's therapeutic platform. The Company is formulating its regulatory and drug development program for its lead drug candidate, SM-88, and working towards the initiation of its Phase II clinical trial. The Company is also evaluating the expansion of its Phase II program to other types of cancer. The Company has not generated any revenue.
Is TYME a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 7.0
52 Week Low 1.93
Average Volume 990,539
200-Day Moving Average 2.7721
50-Day Moving Average 3.0442
20-Day Moving Average 3.256
10-Day Moving Average 3.07
Average True Range 0.4625
ADX 20.59
+DI 35.4879
-DI 23.5088
Chandelier Exit (Long, 3 ATRs ) 3.2525
Chandelier Exit (Short, 3 ATRs ) 3.7075
Upper Bollinger Band 3.9494
Lower Bollinger Band 2.5626
Percent B (%b) 0.75
BandWidth 42.592138
MACD Line -0.0833
MACD Signal Line -0.0139
MACD Histogram -0.0694
Fundamentals Value
Market Cap 321.56 Million
Num Shares 89.3 Million
EPS -0.14
Price-to-Earnings (P/E) Ratio -25.71
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.84
Resistance 3 (R3) 5.76 4.94 5.46
Resistance 2 (R2) 4.94 4.37 4.98 5.34
Resistance 1 (R1) 4.27 4.02 4.61 4.35 5.21
Pivot Point 3.45 3.45 3.62 3.49 3.45
Support 1 (S1) 2.78 2.88 3.12 2.86 1.99
Support 2 (S2) 1.96 2.53 2.00 1.86
Support 3 (S3) 1.29 1.96 1.74
Support 4 (S4) 1.37